NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
Fate Therapeutics
Intima Bioscience, Inc.
Intima Bioscience, Inc.
TCRCure Biopharma Ltd.
AgonOx, Inc.
Iovance Biotherapeutics, Inc.
ImCheck Therapeutics